may have to submit certain information to demonstrate that they have met the standards. b. Cost Study of Local Switching Costs: Price cap LEC are required to conduct a cost study to determine the geographically-average portion of local switching costs that is attributable to the line-side ports, and to dedicated trunk side cards and ports. c. Cost Study of Interstate Access Service that Remain Subject to Price Cap Regulation: To implement our backstop to market-based access charge reform, we require each incumbent price cap LEC to file a cost study no later than February 8, 2001, demonstrating the cost of providing those interstate access services that remain subject to price cap regulation because they do not face substantial competition. d. Tariff Filings: The Commission requires the filing of various tariffs. e. Third-Party Disclosure: In the Second Order on Reconsideration, the Commission requires LECs to provide IXCs with customer-specific information about how many and what type of presubscribed interexchange carrier charges (PICCs) they are assessing for each of the IXC's presubscribed customers. One of the primary goals of the First Report and Order was to develop a cost-recovery mechanism that permits carriers to recover their costs in a manner that reflects the way in which those costs are incurred. Without access to information that indicates whether the LEC is assessing a primary or non-primary residential PICC, or about how many local business lines are presubscribed to a particular IXC, the IXCs will be unable to develop rates that accurately reflect the underlying costs. The information required under these Orders would be used in determining whether the incumbent LECs should receive the regulatory relief proposed in the Orders. The information collected under the Second Order on Reconsideration and Memorandum Opinion and Order would be submitted by the LECs to the interxchange carriers (IXCs) for use in developing the most cost-efficient rates and rate structures.

Federal Communications Commission.

Magalie Roman Salas,

Secretary.

[FR Doc. 98–756 Filed 1–12–98; 8:45 am]

BILLING CODE 6712–01–P

FEDERAL MARITIME COMMISSION

[Petition P1–98]

China Ocean Shipping (Group) Company—Petition for Exemption From Section 9(c) of the Shipping Act of 1984 (Effective Date of Controlled Carrier Rates); Notice of Filing

Notice is hereby given that China Ocean Shipping (Group) Company (''Petitioner'') has petitioned for an exemption pursuant to Section 16 of the Shipping Act of 1984, 46 U.S.C. app. 1715, seeking to be permitted to file rates in the United States cross trades on one day's notice to match (but not to undercut) the rates of competing carriers. The trades affected would be those trades between the United States and all countries other than the People's Republic of China.

In order for the Commission to make a thorough evaluation of the petition for exemption, interested persons are requested to submit views or arguments in reply to the petition no later than February 2, 1998. Replies shall consist of an original and 15 copies, be directed to the Secretary, Federal Maritime Commission, Washington, D.C. 20573–0001, and be served on Petitioner's counsel: Richard D. Gluck, Esq., Garvey, Schubert & Barer, 1000 Potomac Street, N.W., Washington, D.C. 20007.

Copies of the petition are available for examination at the Washington, D.C. office of the Secretary of the Commission, 800 N. Capitol Street, N.W., Room 1046.

Joseph C. Polking,

Secretary.

[FR Doc. 98–768 Filed 1–12–98; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act. Unless otherwise noted, nonbanking activities will be conducted throughout the United States.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than February 6, 1998.

A. Federal Reserve Bank of Cleveland (Jeffery Hirsch, Banking Supervisor) 1455 East Sixth Street, Cleveland, Ohio 44101-2566:

1. Wayne Bancorp, Inc., Wooster, Ohio; to merge with Chippewa Valley Bancshares, Inc., Rittman, Ohio, and thereby indirectly acquire Chippewa Valley Bank, Rittman, Ohio.

B. Federal Reserve Bank of Kansas City (D. Michael Manies, Assistant Vice President) 925 Grand Avenue, Kansas City, Missouri 64198-0001:

1. First Nebraska Bancs, Inc., Sidney, Nebraska; to merge with South Platte Bancorp Julesburg, Colorado, and thereby indirectly acquire First National Bank, Julesburg, Colorado.

Board of Governors of the Federal Reserve System, January 7, 1998.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 98–737 Filed 1-12-98; 8:45 am]

BILLING CODE 6210-01-F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Termination of Travelers' Health Voice Service to the Public

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (DHHS).

ACTION: Notice.

SUMMARY: This notice announces the termination of the availability of Travelers' Health disease and health risk information by voice service to the public.

FOR FURTHER INFORMATION CONTACT: Roz Dewart, Chief, Travelers' Health Section, Division of Quarantine, National Center for Infectious Diseases,

Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Mailstop E–03, Atlanta, GA 30333.

SUPPLEMENTARY INFORMATION: Consistent with OMB A–130 circular, Section 8.a.6.(j), Federal agencies are required to: ''Provide adequate notice when initiating, substantially modifying, or terminating significant information dissemination products * * *''.

The Division of Quarantine's Travelers' Health Voice/Fax service is a major part of the CDC Voice/Fax Information Service. This service allows any caller access to the most current health related information by using a Touch-Tone telephone. The service has been in operation for 7 years, and in the most recent 12-month period received nearly 1 million telephone calls, providing automated voice-response information to those callers; it also provided 1.5 million pages of automated fax information. Information is provided in several levels of detail and complexity to reach a broad audience more effectively, including the general public and health-care professionals.

The Travelers' Health Voice/Fax service is undergoing major renovation. With the innovations in telecommunications technology and the wide availability of fax machines, the voice component of this service is much less effective. The necessarily lengthy text is difficult to listen to and capture all critical recommendations. Analysis of call flow indicated ''caller hang-up'' before the complete message was delivered. Receipt of hard-copy fax documents ensures that travelers and their health-care providers have accurate and comprehensive messages. The fax system also permits their careful review of the complex information. Therefore, the voice component of the Travelers' Health Voice/Fax service will terminate in December 1997. The revised service will provide international travelers and health-care providers a more efficient and user-friendly service. The Travelers' Health Information will be available by fax through a toll-free call. In addition, the same information will be on the Internet on the CDC web site at: http://www.cdc.gov (select Travelers' Health).

Dated: January 7, 1998.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–746 Filed 1–12–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Fees for Consultation Services for Ship Construction and Renovation

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (DHHS).

ACTION: Extension of request for comments.

A notice requesting comments from all interested parties concerning an additional vessel size category for ships >90,000 gross register tonnage and charging fees for consultation services for ship construction and renovation was published in the **Federal Register** on November 17, 1997 (Volume 62, Number 221).

This notice is amended as follows: On page 61336, third column, under the heading **DATES,** the date for submitting written comments to this notice has been extended from January 2, 1998, to January 30, 1998.

All other information and requirements of the November 17, 1997, **Federal Register** notice remain the same.

Dated: January 7, 1998.

Joseph R. Carter,

Acting Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 98–747 Filed 1–12–98; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 97P–0441]

Administrative Proceeding; Re: Pharmanex, Inc.

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of opportunity to comment.

SUMMARY: The Food and Drug Administration (FDA) is announcing that comments related to the regulatory status of Cholestin™ may be submitted until January 30, 1998. This action is being taken as a part of the agency's deliberation on the regulatory status of Cholestin™. All comments postmarked on or before January 30, 1998, will be accepted as part of the official record for this matter.

DATES: Submit written comments by January 30, 1998.

ADDRESSES: Submit written comments regarding this issue to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857, ATTN: Docket 97P–0441.

FOR FURTHER INFORMATION CONTACT: Ilisa B.G. Bernstein, Office of Policy (HF–23), Office of the Commissioner, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–3380, or IBernste@oc.fda.gov.

SUPPLEMENTARY INFORMATION: On October 29, 1997, FDA received a document entitled ''Petition to the Food and Drug Administration for a Stay of Action With Respect to Cholestin™ Dietary Supplement,'' (petition) from Pharmanex, Inc. (Pharmanex). The petition requested FDA to stay the effect of a September 30, 1997, FDA letter to Pharmanex discussing the regulatory status of Cholestin™, and to also stay any form of enforcement action adverse to Pharmanex or Cholestin™. In response to the petition, in a letter dated November 14, 1997, from William Schultz, FDA's Deputy Commissioner for Policy, to Stuart Pape, Counsel to Pharmanex, Inc., the agency informed the petitioner that it was not acting on the petition because there was no administrative action taken by the Commissioner of Food and Drugs capable of being stayed, and because FDA decisions to take enforcement actions are not subject to petitions or other action by interested persons outside the agency. In the November 14, 1997 letter, the agency also informed the petitioner that it was initiating an administrative proceeding under 21 CFR 10.25(b) to decide the regulatory status of Cholestin™. The agency stated that it would use its ''best efforts'' to conclude the proceeding by the end of 1997.

Since the November 14, 1997, letter was issued, FDA has received a number of comments regarding the regulatory status of Cholestin™, including three additional submissions from Pharmanex (one received by the agency on December 29, 1997). Several requests for extensions of time to submit comments have also been received. Under the circumstances, it is apparent that additional time is required to afford all interested parties adequate opportunity to submit comments in this matter.

With this notice the agency announces that comments related to this matter may be submitted until January 30, 1998. All comments postmarked on or before January 30, 1998, will be accepted as part of the official record for this matter. Comments should be sent to the Dockets Management Branch (address above) and should be identified